

# Luciano Potena

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1143444/publications.pdf>

Version: 2024-02-01

182  
papers

7,835  
citations

70961

41  
h-index

56606

83  
g-index

192  
all docs

192  
docs citations

192  
times ranked

8032  
citing authors

#	ARTICLE	IF	CITATIONS
1	The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1-23.	0.3	1,096
2	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heartâ€“lung transplantation Reportâ€“2019; Focus theme: Donor and recipient size match. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1042-1055.	0.3	711
3	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report â€“ 2019; focus theme: Donor and recipient size match. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1056-1066.	0.3	597
4	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 1505-1535.	2.9	555
5	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report â€“ 2021; Focus on recipient characteristics. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1060-1072.	0.3	233
6	Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial. <i>American Journal of Transplantation</i> , 2013, 13, 1203-1216.	2.6	201
7	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric heart transplantation report â€“ 2019; Focus theme: Donor and recipient size match. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1028-1041.	0.3	159
8	Prognostic Implications of Serial Assessments of Pulmonary Hypertension in Severe Chronic Heart Failure. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 1241-1246.	0.3	155
9	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation reportâ€“2020; focus on deceased donor characteristics. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1003-1015.	0.3	150
10	Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Leftâ€“Ventricular Systolicâ€“Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 299-311.	1.2	148
11	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report â€“ 2021; Focus on recipient characteristics. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1035-1049.	0.3	132
12	Acute Rejection and Cardiac Allograft Vascular Disease Is Reduced by Suppression of Subclinical Cytomegalovirus Infection. <i>Transplantation</i> , 2006, 82, 398-405.	0.5	128
13	The management of antibodies in heart transplantation: An ISHLT consensus document. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 537-547.	0.3	114
14	Building a tissue-based molecular diagnostic system in heart transplant rejection: The heart Molecular Microscope Diagnostic (MMDx) System. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1192-1200.	0.3	107
15	The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2016, 100, 39-53.	0.5	105
16	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric lung and heart-lung transplantation reportâ€“2019; Focus theme: Donor and recipient size match. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1015-1027.	0.3	97
17	Identification ofâ€“ATTR-Related Subclinical Amyloidosis Withâ€“99mTc-DPD Scintigraphy. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 531-532.	2.3	91
18	T-Cell Immunity to Subclinical Cytomegalovirus Infection Reduces Cardiac Allograft Disease. <i>Circulation</i> , 2006, 114, 1608-1615.	1.6	89

#	ARTICLE	IF	CITATIONS
19	Hydroxymethyl-Glutaryl Coenzyme A Reductase Inhibition Limits Cytomegalovirus Infection in Human Endothelial Cells. <i>Circulation</i> , 2004, 109, 532-536.	1.6	85
20	Cytomegalovirus-associated allograft rejection in heart transplant patients. <i>Current Opinion in Infectious Diseases</i> , 2007, 20, 425-431.	1.3	85
21	Prophylaxis Versus Preemptive Anti-cytomegalovirus Approach for Prevention of Allograft Vasculopathy in Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 461-467.	0.3	83
22	Update and Review: State-of-the-Art Management of Cytomegalovirus Infection and Disease Following Thoracic Organ Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, S1-S17.	0.3	83
23	MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1353-1362.	0.3	75
24	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 23rd pediatric heart transplantation report 2020; focus on deceased donor characteristics. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1028-1037.	0.3	73
25	Heart Transplantation in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2008, 101, 387-392.	0.7	70
26	Safety and Efficacy of Two Types of Influenza Vaccination in Heart Transplant Recipients: A Prospective Randomised Controlled Study. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 588-592.	0.3	69
27	Clinical relevance of the International Society for Heart and Lung Transplantation consensus classification of primary graft dysfunction after heart transplantation: Epidemiology, risk factors, and outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1217-1225.	0.3	66
28	Differential Effect of Everolimus on Progression of Early and Late Cardiac Allograft Vasculopathy in Current Clinical Practice. <i>American Journal of Transplantation</i> , 2013, 13, 1217-1226.	2.6	62
29	Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. <i>Reviews in Medical Virology</i> , 2013, 23, 97-125.	3.9	60
30	Design and Implementation of the International Genetics and Translational Research in Transplantation Network. <i>Transplantation</i> , 2015, 99, 2401-2412.	0.5	60
31	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult lung transplantation report 2020; focus on deceased donor characteristics. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1016-1027.	0.3	60
32	Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. <i>Transplantation</i> , 2003, 75, 839-843.	0.5	59
33	Everolimus is associated with a reduced incidence of cytomegalovirus infection following <i>de novo</i> cardiac transplantation. <i>Transplant Infectious Disease</i> , 2013, 15, 150-162.	0.7	58
34	Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: Long-term follow-up of the SHIRAKISS randomized, prospective study. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 565-570.	0.3	56
35	The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions. <i>American Journal of Transplantation</i> , 2017, 17, 42-53.	2.6	55
36	Accelerated QRS widening as an independent predictor of cardiac death or of the need for heart transplantation in patients with congestive heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2002, 21, 899-901.	0.3	54

#	ARTICLE	IF	CITATIONS
37	mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?. <i>Transplantation Reviews</i> , 2015, 29, 93-102.	1.2	47
38	Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1146-1153.	0.3	45
39	Changes in Coronary Arterial Dimensions Early After Cardiac Transplantation. <i>Transplantation</i> , 2007, 83, 700-705.	0.5	44
40	Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 710-715.	0.3	43
41	Psychological Predictors of Mortality in Heart Transplanted Patients: A Prospective, 6-Year Follow-Up Study. <i>Transplantation</i> , 2010, 89, 879-886.	0.5	43
42	An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 636-646.	0.3	43
43	Exploring the cardiac response to injury in heart transplant biopsies. <i>JCI Insight</i> , 2018, 3, .	2.3	43
44	Complications of Cardiac Transplantation. <i>Current Cardiology Reports</i> , 2018, 20, 73.	1.3	39
45	Delayed Acquisition of High Avidity Anti Cytomegalovirus Antibody Is Correlated with Prolonged Antigenemia in Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 1998, 178, 1145-1149.	1.9	36
46	New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 99-105.	1.4	36
47	Serial versus isolated assessment of clinical and instrumental parameters in heart failure: prognostic and therapeutic implications. <i>American Heart Journal</i> , 2003, 146, 298-303.	1.2	34
48	Multicenter Prospective Study for Laboratory Diagnosis of HHV8 Infection in Solid Organ Donors and Transplant Recipients and Evaluation of the Clinical Impact After Transplantation. <i>Transplantation</i> , 2017, 101, 1935-1944.	0.5	34
49	Distance between Patients' Subjective Perceptions and Objectively Evaluated Disease Severity in Chronic Heart Failure. <i>Psychotherapy and Psychosomatics</i> , 2003, 72, 166-170.	4.0	32
50	Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	32
51	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric heart transplantation report " 2021; focus on recipient characteristics. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1050-1059.	0.3	32
52	Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 619-626.	0.3	31
53	P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. <i>Journal of Clinical Investigation</i> , 2018, 128, 3490-3503.	3.9	31
54	Identification and Classification of Acute Cardiac Rejection by Intragraft Transcriptional Profiling. <i>Circulation</i> , 2011, 123, 2236-2243.	1.6	30

#	ARTICLE	IF	CITATIONS
55	Cyclosporine Lowering With Everolimus or Mycophenolate to Preserve Renal Function in Heart Recipients: A Randomized Study. <i>Transplantation</i> , 2010, 89, 263-265.	0.5	29
56	Frequent Occult Infection with Cytomegalovirus in Cardiac Transplant Recipients despite Antiviral Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1804-1810.	1.8	28
57	Ischemic injury activates PTHrP and PTH1R expression in human ventricular cardiomyocytes. <i>Basic Research in Cardiology</i> , 2009, 104, 427-434.	2.5	28
58	Everolimus immunosuppression in de novo heart transplant recipients: What does the evidence tell us now?. <i>Transplantation Reviews</i> , 2013, 27, 76-84.	1.2	28
59	Optimizing the Safety Profile of Everolimus by Delayed Initiation in De Novo Heart Transplant Recipients. <i>Transplantation</i> , 2018, 102, 493-501.	0.5	28
60	Long-Term Safety and Effectiveness of Statins for Heart Transplant Recipients in Routine Clinical Practice. <i>Transplantation Proceedings</i> , 2006, 38, 1507-1510.	0.3	27
61	Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1611-1622.	0.9	27
62	Inflammatory Cell Burden and Phenotype in Endomyocardial Biopsies With Antibody-Mediated Rejection (AMR): A Multicenter Pilot Study From the AECVP. <i>American Journal of Transplantation</i> , 2015, 15, 526-534.	2.6	26
63	Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions. <i>Clinical Transplantation</i> , 2011, 25, E475-86.	0.8	24
64	Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation. <i>Transplantation</i> , 2016, 100, S19-S26.	0.5	24
65	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric lung transplantation report " 2021; Focus on recipient characteristics. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1023-1034.	0.3	24
66	Interplay Between Systemic Inflammation and Markers of Insulin Resistance in Cardiovascular Prognosis After Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 324-330.	0.3	23
67	Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies. <i>European Heart Journal</i> , 2022, 43, 2237-2246.	1.0	23
68	Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2019, 291, 77-82.	0.8	22
69	COVID-19 and education: restructuring after the pandemic. <i>Transplant International</i> , 2021, 34, 220-223.	0.8	22
70	Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 334-344.	0.3	21
71	Asymmetric Dimethylarginine and Cardiac Allograft Vasculopathy Progression: Modulation by Sirolimus. <i>Transplantation</i> , 2008, 85, 827-833.	0.5	20
72	Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1305-1311.	0.3	20

#	ARTICLE	IF	CITATIONS
73	Medium-term outcome of recipients of marginal donor hearts selected with new stress-echocardiographic techniques over standard criteria. <i>Cardiovascular Ultrasound</i> , 2014, 12, 20.	0.5	20
74	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	2.9	20
75	Hospitalization for congestive heart failure: is it still a cardiology business?. <i>European Journal of Heart Failure</i> , 2002, 4, 99-104.	2.9	19
76	Cytomegalovirus Immunoglobulin After Thoracic Transplantation. <i>Transplantation</i> , 2016, 100, S1-S4.	0.5	19
77	Antibody-mediated rejection in heart transplantation. <i>Current Opinion in Organ Transplantation</i> , 2017, 22, 207-214.	0.8	19
78	Viral genome search in myocardium of patients with fulminant myocarditis. <i>European Journal of Heart Failure</i> , 2020, 22, 1277-1280.	2.9	19
79	Safety and Efficacy of Ezetimibe With Low Doses of Simvastatin in Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 685-688.	0.3	18
80	Post-discharge arrhythmic risk stratification of patients with acute myocarditis and life-threatening ventricular tachyarrhythmias. <i>European Journal of Heart Failure</i> , 2021, 23, 2045-2054.	2.9	17
81	Impaired Dendritic Cell Immunophenotype and Function in Heart Transplant Patients Undergoing Active Cytomegalovirus Infection. <i>Transplantation</i> , 2005, 79, 219-227.	0.5	16
82	Homocysteine-Lowering Therapy and Early Progression of Transplant Vasculopathy: A Prospective, Randomized, IVUS-Based Study. <i>American Journal of Transplantation</i> , 2005, 5, 2258-2264.	2.6	16
83	Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 24-32.	1.1	16
84	An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients. <i>Transplantation Reviews</i> , 2021, 36, 100655.	1.2	15
85	Implications of cardiac resynchronization therapy and prophylactic defibrillator implantation among patients eligible for heart transplantation. <i>American Journal of Cardiology</i> , 2004, 93, 371-373.	0.7	14
86	miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy. <i>American Journal of Transplantation</i> , 2021, 21, 3280-3295.	2.6	14
87	Cardiac Allograft Vasculopathy and Insulin Resistance—Hope for New Therapeutic Targets. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 965-981.	1.2	13
88	Occurrence of Fatal and Nonfatal Adverse Outcomes after Heart Transplantation in Patients with Pretransplant Noncytotoxic HLA Antibodies. <i>Journal of Transplantation</i> , 2013, 2013, 1-6.	0.3	13
89	Coronary artery disease in heart transplantation: new concepts for an old disease. <i>Transplant International</i> , 2018, 31, 787-827.	0.8	13
90	Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort. <i>Microorganisms</i> , 2022, 10, 1021.	1.6	13

#	ARTICLE	IF	CITATIONS
91	Prevalence of Substance-Related Disorders in Heart Transplantation Candidates. <i>Transplantation Proceedings</i> , 2007, 39, 1970-1972.	0.3	12
92	Heart allograft preservation. <i>Current Opinion in Cardiology</i> , 2017, 32, 292-300.	0.8	12
93	Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 263.	1.2	12
94	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-third pediatric lung transplantation report "2020; focus on deceased donor characteristics. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1038-1049.	0.3	12
95	Pediatric Restrictive Cardiomyopathies. <i>Frontiers in Pediatrics</i> , 2021, 9, 745365.	0.9	12
96	Cytomegalovirus Management in Solid Organ Transplant Recipients: A Pre-COVID-19 Survey From the Working Group of the European Society for Organ Transplantation. <i>Transplant International</i> , 0, 35, .	0.8	12
97	The International Society for Heart and Lung Transplantation Registries in the Era of Big Data With Global Reach. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1225-1232.	0.3	11
98	Heart Transplant and Hepato-Renal Dysfunction: The Model of End-Stage Liver Disease Excluding International Normalized Ratio as a Predictor of Postoperative Outcomes. <i>Transplantation Proceedings</i> , 2019, 51, 2962-2966.	0.3	11
99	Prevalence of Medication Nonadherence to Co-medication Compared to Immunosuppressants in Heart Transplant Recipients: Findings From the International Cross-sectional BRIGHT Study. <i>Clinical Therapeutics</i> , 2019, 41, 130-136.	1.1	11
100	Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3391-3409.	2.0	11
101	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	1.4	10
102	Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C>T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 1245-1251.	0.3	9
103	Pretransplant Right Ventricular Dysfunction Is Associated With Increased Mortality After Heart Transplantation: A Hard Inheritance to Overcome. <i>Journal of Cardiac Failure</i> , 2022, 28, 259-269.	0.7	9
104	Relevance of cardioverter defibrillators for the prevention of sudden cardiac death on the timing of heart transplantation. <i>Clinical Transplantation</i> , 2006, 20, 684-688.	0.8	8
105	Changes in exercise capacity induced by heart transplantation: prognostic and therapeutic implications. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2011, 21, 519-525.	1.3	8
106	Extracorporeal Membrane Oxygenation Support System as Bridge to Solution in Refractory Cardiogenic Shock. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S186.	0.3	8
107	Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review. <i>Journal of Nephrology</i> , 2020, 33, 69-82.	0.9	8
108	Manifestations of health anxiety in patients with heart transplant. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 364-369.	0.8	8

#	ARTICLE	IF	CITATIONS
109	Outcome of patients on heart transplant list treated with a continuous-flow left ventricular assist device: Insights from the TRAns-Atlantic registry on VAd and TrAnsplant (TRAVIATA). International Journal of Cardiology, 2021, 324, 122-130.	0.8	8
110	Prognostic Stratification of Women With Chronic Heart Failure Referred for Heart Transplantation: Relevance of Gender as Compared With Gender-related Characteristics. Journal of Heart and Lung Transplantation, 2006, 25, 648-652.	0.3	7
111	Long-Term Effect of Folic Acid Therapy in Heart Transplant Recipients: Follow-Up Analysis of a Randomized Study. Transplantation, 2008, 85, 1146-1150.	0.5	7
112	Soluble HLA-G pre-transplant levels to identify the risk for development of infection in heart transplant recipients. Human Immunology, 2020, 81, 147-150.	1.2	7
113	The pharmaceutical management of cardiac allograft vasculopathy after heart transplantation. Expert Opinion on Pharmacotherapy, 2020, 21, 1367-1376.	0.9	7
114	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. ESC Heart Failure, 2021, 8, 4409-4424.	1.4	7
115	Prophylaxis Versus Preemptive Therapy for Prevention of the Consequences of Cytomegalovirus Infection in Transplant Recipients: A Still Unresolved Issue. Transplantation, 2009, 87, 305-306.	0.5	6
116	Donor risk analysis and validation in heart transplants: a single-centre experience. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 860-867.	0.5	6
117	Folate supplementation after heart transplantation: effects on homocysteine plasma levels and allograft vascular disease. Clinical Nutrition, 2002, 21, 245-248.	2.3	5
118	Peripheral Blood Leukocyte Counts in Cytomegalovirus Infected Heart Transplant Patients: Impact of Acute Disease Versus Subclinical Infection. Transplantation, 2006, 82, 1419-1424.	0.5	5
119	Postoperative outcomes following rehabilitation in patients with left ventricular assist devices. Monaldi Archives for Chest Disease, 2020, 90, .	0.3	5
120	Covid-19 in recipients of heart and lung transplantation: Learning from experience. Journal of Heart and Lung Transplantation, 2021, 40, 948-950.	0.3	5
121	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. ESC Heart Failure, 2021, 8, 4394-4408.	1.4	5
122	Right Heart Catheterization in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 647-660.	1.0	5
123	Heart rate reserve during dipyridamole stress test applied to potential heart donors in brain death. Minerva Cardioangiologica, 2020, 68, 249-257.	1.2	5
124	Cardiovascular implantable electronic device therapy in patients with left ventricular assist devices: insights from TRAVIATA. International Journal of Cardiology, 2021, 340, 26-33.	0.8	4
125	Age and heart transplantation: results from a heart failure management unit. Clinical Transplantation, 2008, 22, 150-155.	0.8	3
126	Prognostic stratification and treatment of cardiac light chain amyloidosis: A narrow path in the jungle. Journal of Heart and Lung Transplantation, 2014, 33, 136-138.	0.3	3

#	ARTICLE	IF	CITATIONS
127	The Conundrum of Equitable Organ Allocation in Heart Transplantation. <i>Transplantation</i> , 2017, 101, 1969-1970.	0.5	3
128	Molecular Assessment of Heart Transplant Biopsies. <i>Transplantation</i> , 2018, 102, S62-S63.	0.5	3
129	Donor-derived human herpesvirus 8 infection with Kaposi sarcoma and Kaposi sarcoma inflammatory cytokine syndrome in a heart transplant recipient: A case report. <i>Transplant Infectious Disease</i> , 2021, 23, e13609.	0.7	3
130	Cytomegalovirus and Heart Transplant Atherosclerosis: A Likely Guilt Hidden by Weak Proofs. <i>Transplantation</i> , 2004, 78, 631.	0.5	2
131	Static and Dynamic Predictors of Adverse Events in Patients with Intermediate Cardiopulmonary Capacity Referred for Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 85-89.	0.3	2
132	Reproducibility of IVUS measurements in heart transplant recipients: Increased quality of data by using dedicated software for image analysis. , 2008, , .		2
133	Everolimus and Valganciclovir Prophylaxis: How to Chase CMV But Not the Patient: Insights From PROTECT Randomized Study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S305.	0.3	2
134	Cholesterol efflux capacity: A weak player in the complex plot of cardiac allograft vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1286-1288.	0.3	2
135	Quantiferon Monitor: A Novel Assay for Prediction of Infectious Risk in Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, S106.	0.3	2
136	Outcomes of Heart Transplantation for Transthyretin-Related Amyloid Cardiomyopathy. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, S63-S64.	0.3	2
137	Pregnancy and Heart Transplantation. <i>Transplantation</i> , 2018, 102, 1411-1412.	0.5	2
138	Quantiferon Monitor Assay Identifies Over-Immunosuppressed Patients with Adverse Outcomes After Heart Transplantation: Towards the Definition of a Phenotype of Immune Frailty. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, S19-S20.	0.3	2
139	Does the antibody mediated rejection grading scale have prognostic prediction? Yes, but the picture is still blurry. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 265-270.	0.8	2
140	Management of heart transplant candidates in the time of COVID-19 pandemic: Looking for answers. <i>American Journal of Transplantation</i> , 2020, 20, 2956-2957.	2.6	2
141	Impact of Predicted Heart Mass-Based Donor-Recipient Size Matching on Transplant Outcomes. <i>Transplantation Proceedings</i> , 2022, 54, 774-781.	0.3	2
142	Nitrates and Angina: an insight into arterial and venular involvement in blood flow regulation. <i>Physica Medica</i> , 2005, 21, 81-85.	0.4	1
143	474: Interaction of CMV Prophylaxis and Pre-Emptive Strategies with Immunosuppressive Therapy: Potential Antiviral Effect of Everolimus. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, S155-S156.	0.3	1
144	649 Study Design and Preliminary Results of the Italian Everolimus Registry CERTIC. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, S223-S224.	0.3	1

#	ARTICLE	IF	CITATIONS
145	Inflammatory Cell Burden and Phenotype in Endomyocardial Biopsies from Patients with Antibody-Mediated Rejection (AMR) – An AECVP Multicenter Study. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S19.	0.3	1
146	Epidemiology, Mortality and Risk Factors of Primary and Secondary Graft Failure According with ISHLT Consensus Criteria. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, S173.	0.3	1
147	Influence of Angiotensin-Type1-Receptor Antibodies in Chronic Vascular Injury on Heart Transplant Patients. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S99-S100.	0.3	1
148	Donor Selection Criteria: Clinical and Pathological Insights. , 2016, , 115-135.		1
149	Unraveling the Process of the Dying Heart. <i>Transplantation</i> , 2016, 100, 2521-2523.	0.5	1
150	Validating the INTERHEART Classifiers for Molecular Diagnosis of Rejection in 558 New Endomyocardial Biopsies. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, S303-S304.	0.3	1
151	Liver and kidney function in refractory heart failure: The narrow gate to achieve post-transplant survival. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 115-116.	0.7	1
152	Longest reported support (7.5 years) with postauricular type of Jarvik 2000 axial-flow left ventricular assist device. <i>Journal of Artificial Organs</i> , 2021, 24, 503-506.	0.4	1
153	Graft Failure/Dysfunction: Clinical Issues and Role of Endomyocardial Biopsy. , 2016, , 155-169.		1
154	Novel therapeutic and diagnostic management of heart transplant patients. <i>Heart, Lung and Vessels</i> , 2015, 7, 198-207.	0.4	1
155	Impact of prior sternotomy on survival and allograft function after heart transplantation: A single center matched analysis. <i>Journal of Cardiac Surgery</i> , 2022, , .	0.3	1
156	Relationship between psychiatric disorders and physical status during the course of a heart transplantation program: a prospective, longitudinal study. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2005, 6, 900-3.	0.1	1
157	Role of Quantitative Flow Ratio in Predicting Future Cardiac Allograft Vasculopathy in Heart Transplant Recipients. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, e011656.	1.4	1
158	Time course and determinants of graft vascular remodelling in heart transplant recipients: a prospective study. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 195.	0.3	0
159	Aggressive anti-cytomegalovirus prophylaxis and acute rejection in high risk patients: Beat the virus and prevent the rejection. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, S117-S118.	0.3	0
160	273. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, S138-S139.	0.3	0
161	Potential of Medical Treatment, Device Therapy, and Conventional Surgery in Patients Referred for Heart Transplantation. <i>Journal of Cardiac Surgery</i> , 2007, 22, 456-458.	0.3	0
162	186: Role of NT-proBNP and Right Heart Catheterization Measurements in Predicting Outcome of Patients Referred for Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, S127-S128.	0.3	0

#	ARTICLE	IF	CITATIONS
163	Comparison of Polymerase Chain Reaction of Polymorphonuclear Leukocytes and Plasma Identifies Patients Who Control Cytomegalovirus Infection after Hematopoietic Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2008, 47, 535-539.	2.9	0
164	Frequent Occult Infection with Cytomegalovirus in Cardiac Transplant Recipients despite Antiviral Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2008, 46, 4121-4121.	1.8	0
165	34: C4d Detection and Outcome in Long-Term Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, S76-S77.	0.3	0
166	171 Lower Incidence of Viral Infections with Everolimus Versus MMF in De Novo Heart Transplant Recipients: 12 Month Analysis of a Randomized Multicenter Study. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, S63-S64.	0.3	0
167	24-Month Safety and Efficacy of Concentration Controlled Everolimus with Reduced Cyclosporine Versus Mycophenolate Mofetil in 721 De Novo Heart Transplant Recipients: Results from the A2310 Study. <i>Transplantation</i> , 2012, 94, 127.	0.5	0
168	169 Interplay between Pulmonary Hypertension and Donor-Recipient Matching in the Risk for Early Graft Failure after Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, S65-S66.	0.3	0
169	Clinical and Prognostic Correlates of pAMR Grading in Patients with Suspect Antibody Mediated Rejection. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S103.	0.3	0
170	Late Changes in Maximal Intimal Thickness after Heart Transplant: Prognostic Implications and Risk Factors. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S33-S34.	0.3	0
171	Reconstitution of CMV-Specific Immunity After Heart Transplantation May Guide Customization of Immunosuppressive and Antiviral Strategies: A Prospective Randomized Study. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, S154-S155.	0.3	0
172	Correlation Between Lipid Levels and Cardiovascular Events in Heart Transplant Recipients: 24-Month Analysis of the A2310 Study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S60.	0.3	0
173	Extracorporeal Membrane Oxygenation Support in Refractory Cardiogenic Shock: Outcome, Treatment Strategies and Analysis of Risk Factors. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S192-S193.	0.3	0
174	Antithymocyte Globulins in Heart Transplantation. <i>Transplantation</i> , 2016, 100, 483-484.	0.5	0
175	Cardiac Transplantation and the Contribution of Pathology. , 2016, , 3-10.		0
176	Current Perspectives on Cytomegalovirus in Heart Transplantation. <i>Current Transplantation Reports</i> , 2016, 3, 358-366.	0.9	0
177	Risk Stratification to Improve Transplant Benefit in Older Candidates: Are All Comorbidities Created Equal?. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, S27-S28.	0.3	0
178	Development of post-transplant risk scores: Dancing to off-key tunes. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1668-1669.	0.3	0
179	Advanced Heart Failure: From Pathophysiology to Clinical Management. <i>Heart Failure Clinics</i> , 2021, 17, i.	1.0	0
180	Management of Advanced Heart Failure: The Science of Uncertainty and the Art of Probability. <i>Heart Failure Clinics</i> , 2021, 17, xv-xvi.	1.0	0

#	ARTICLE	IF	CITATIONS
181	Malignancies After Heart Transplantation. , 2016, , 329-352.		0
182	Candidacy for heart transplantation in adult congenital heart disease patients: A cohort study. International Journal of Cardiology Congenital Heart Disease, 2022, 8, 100363.	0.2	0